Anti elavl1 antibody

The transfected cells were treated with 20 μM MG132 (Sigma Aldrich) for 6 h, which was followed by cell lysis for immunoprecipitation. The cell lysates were incubated overnight with Protein-A/G MagBeads (Yeasen, Shanghai, China) and anti-ELAVL1 antibody (Cell Signaling Technology) or normal rabbit IgG (Cell Signaling Technology) at 4 °C. The protein complexes were retrieved, washed, and subjected to western blotting with an anti-ubiquitin antibody (Cell Signaling Technology) [23 (link)].

A total of 77 pairs of tumor and adjacent non-tumor tissues were subjected to clinicopathological analyses. Written informed consent was obtained from all patients. Paraffin-embedded tumor tissues and the surrounding non-tumor tissues were examined via H&E staining and immunohistochemistry with anti-ELAVL1 antibody (Cell Signaling Technology). Based on the ELAVL1 expression in the nuclei of cells, tumor and non-tumor tissues were classified as follows: negative, partial expression (<50% of nuclei), and diffuse expression (≥50% of nuclei). HCCs with negative or partial ELAVL1 expression were classified as the ELAVL1^low group, whereas HCCs with diffuse ELAVL1 expression were classified as the ELAVL1^high group. All patients received postoperative radiological follow-up every 2–6 months. Radiological assessments were evaluated based on the response evaluation criteria in solid tumors [39 (link)]. This study was approved by the research ethics committees of the Graduate School of Medicine, Chiba University (approval number: 3300) and performed according to the Declaration of Helsinki.